Market Place
Sourcing Support
AC Immune Starts Last Cohort In Phase 1B/2 ABATE Trial
30 Apr 2026 //
GLOBENEWSWIRE
AC Immune Revises Morphomer Tau Deal With Lilly
07 Apr 2026 //
GLOBENEWSWIRE
AC Immune Unveils TDP-43 Brain Pathology Images from ACI-19626
19 Mar 2026 //
GLOBENEWSWIRE
AC Immune To Host Parkinson`s Disease Symposium At AD/PD 2026
05 Mar 2026 //
GLOBENEWSWIRE
AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor
24 Feb 2026 //
GLOBENEWSWIRE
J&J Halts Enrollment in Trial of AC Immune Alzheimer`s drug
19 Feb 2026 //
FIERCE BIOTECH
5 Investigational Therapies Revolutionizing Parkinson Landscape
26 Jan 2026 //
BIOSPACE
AC Immune`s ACI-7104.056 Shows Promise In Slowing Parkinson
12 Dec 2025 //
GLOBENEWSWIRE
AC Immune To Present At Jefferies 2025 London Health Conference
12 Nov 2025 //
PHARMIWEB
AC Immune To Present At Jefferies 2025 London Health Conference
11 Nov 2025 //
PHARMIWEB
AC Immune Appoints Name Neurologist Catherine to Advisory Board
28 Oct 2025 //
GLOBENEWSWIRE
AC Immune`s Anti-Ptau Immunotherapy Phase 1b/2a Trial Results
25 Sep 2025 //
GLOBENEWSWIRE
AC Immune Reduces Workforce by 30%, Trims Pipeline
04 Sep 2025 //
FIERCE BIOTECH
AC Immune Reports Q2 2025 Financials and Updates on Corporate
05 Aug 2025 //
GLOBENEWSWIRE
AC Immune Reports Positive Interim Results from ACI-7104.056 Trial
02 Apr 2025 //
GLOBENEWSWIRE
AC Immune to Present Active Immunotherapies at AD/PD™ 2025
25 Mar 2025 //
GLOBENEWSWIRE
AC Immune Reports 2024 Financial Results and Corporate Update
13 Mar 2025 //
GLOBENEWSWIRE
AC Immune to Participate in Upcoming Investor Conferences
04 Mar 2025 //
GLOBENEWSWIRE
AC Immune Shares Safety Data From ACI-24.060 In Down Syndrome
10 Dec 2024 //
GLOBENEWSWIRE
AC Immune Claims New Alzheimer`s ADC Has `Landmark` Potential
31 Jul 2024 //
FIERCE BIOTECH
AC Immune Unveils Novel ADC Technology at AAIC 2024
31 Jul 2024 //
GLOBENEWSWIRE
AC Immune Showcases MorADC Platform At AAIC 2024
16 Jul 2024 //
GLOBENEWSWIRE
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22 Jan 2024 //
GLOBENEWSWIRE
AC Immune Receives FDA Fast Track Designation for ACI-24.060, to Treat Alzheimer
27 Jun 2023 //
GLOBENEWSWIRE
AC Immune to Host Key Opinion Leader Webinar on Prevention of Alzheimer`s Disease
05 Apr 2023 //
GLOBENEWSWIRE
AC Immune reports positive data from Alzheimer’s disease vaccine trial
27 Jan 2023 //
CLINICAL TRIALS ARENA
AC Immune`s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer`s Shows Safety
26 Jan 2023 //
GLOBENEWSWIRE
